MILLIPLEX^® Mouse CD8 + T Cell Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 15 analytes in mouse serum, plasma, and cell culture supernatants.

Analytes included: sCD137, sFas, sFAS ligand, GM-CSF, Granzyme B, IFNγ, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1β, RANTES, TNF-α

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Enhanced Productivity: Multiplexing reduces sample volume and assay time, allowing for high-throughput analysis.

Comprehensive Immune Profiling: Enables detailed characterization of CD8+ T cell responses, crucial for immunology and oncology research.

Cost-Effective: Saves resources by analyzing multiple biomarkers in a single well.

Reliable and Reproducible: High-quality reagents and standardized protocols ensure consistent results across experiments.

Supports Therapeutic Development: Ideal for evaluating immune modulation, vaccine efficacy, and tumor immunology.

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.